Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. (CLDX) is a healthcare company (biotechnology) based in the United States. The share price is $28.10, down 1.71% on the day, which values the company at $2.21B. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$28.10−1.71% today
Market value
$2.21B
Funk Score
22/100
Against its own history
Well above its usual priceusual price $6.48
200-week average
$31.0710% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Celldex Therapeutics, Inc. in more detail

CLDX trades at -6.7× next year's expected earnings, 13969.1× sales. Measured against its own history, the price is 334% above what its usual multiples would imply ($6.48) — well above its usual price. It sits 10% below its 200-week average of $31.07.

Over the last five fiscal years Celldex Therapeutics, Inc. has compounded revenue -26.9% a year. Its Funk Score is 22 out of 100 (financial strength 7.5, profitability 0.0, growth 1.3, value 0.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

1 of the superinvestors tracked here hold CLDX, including Julian and Felix Baker (0.2% of the portfolio).

Superinvestors holding CLDX

1 of the investors tracked here report a position in their latest 13F filing.

Celldex Therapeutics, Inc. (CLDX): questions and answers

What is Celldex Therapeutics, Inc.'s market cap?

Celldex Therapeutics, Inc. is valued at $2.21B at a share price of $28.10.

Is CLDX overvalued or undervalued?

Against its own history, CLDX is well above its usual price: the price is 334% above the $6.48 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is CLDX above its 200-week moving average?

No. CLDX is 9.5% below its 200-week average of $31.07. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Celldex Therapeutics, Inc. growing?

Over the last five fiscal years Celldex Therapeutics, Inc.'s revenue grew -26.9% a year; over ten years revenue grew -11.9% a year.

Does CLDX pay a dividend?

Celldex Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own CLDX?

In their latest quarterly filings, Julian and Felix Baker (0.2% of the portfolio) hold CLDX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Celldex Therapeutics, Inc. (CLDX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CLDX

Underlying data: Yahoo Finance; company filings with the SEC.